NCT06801015

Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions

A Randomized, Placebo-Controlled Trial of the Effects of Long-Acting GLP-1 or Dual Incretin (GLP-1 and GIP) Modulation on Gastric Motor Functions

• Status: Active Not Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare effects of weekly SQ semaglutide 2.4mg SQ, SQ tirzepatide 10mg, and placebo administered for 24 weeks on GES measured repeatedly at baseline, 16 weeks, 24 weeks, 28 weeks, 4 weeks after stopping the medication, and accommodation and satiation at 24 weeks compared to baseline.

Conditions

• Obesity

Interventions

Type	Name	Description
DRUG	Semaglutide	Both interventions are approved by FDA for the treatment of obesity and are administered by subcutaneous injection once per week
DRUG	Tirzepatide	Both interventions are approved by FDA for the treatment of obesity and are administered by subcutaneous injection once per week
DRUG	Placebo	Placebo administered by subcutaneous injection once per week.

Timeline

• Start date: 2025-10-01
• Primary completion: 2028-01-31
• Completion: 2028-03-31
• First posted: 2025-01-30
• Last updated: 2025-12-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study